Thesis
Cemsidomide's 53% Phase 1 ORR sets up MOMENTUM Phase 2 as the binary that determines whether a cereblon degrader can reach approval in late-line RRMM
Cemsidomide, a cereblon E3 ligase modulator, targets fourth-line or later RRMM patients who have exhausted standard options including anti-CD38 agents and immunomodulatory drugs. The thesis resolves on whether the MOMENTUM Phase 2 trial delivers an ORR sufficient to support FDA accelerated approval via NDA submission targeted for Q4 2028. The primary competitive risk is displacement of the late-line RRMM patient population by approved BCMA-directed CAR-T therapies — ide-cel and cilta-cel — and BCMA-targeted bispecifics such as teclistamab and elranatamab, which are moving earlier and shrinking the addressable fourth-line pool.
Focus
Cemsidomide Phase 2 ORR data readout
H2 2027
Bull
A positive outcome would be an ORR at or above the Phase 1 benchmark of 53% at the 100µg dose, accompanied by deep responses (sCR/VGPR rates consistent with the 26% seen in Phase 1) and a manageable, reproducible safety profile with limited discontinuations. This would validate cemsidomide as the first cereblon degrader to reach a late-line RRMM approval package, immediately trigger NDA preparation, and likely accelerate partnership or M&A interest given the clean mechanism and oral administration.
Bear
The most likely failure modes are ORR compression relative to Phase 1 — common when single-arm Phase 1 signals revert toward the mean in a more controlled Phase 2 setting — or an ORR that falls below the threshold FDA accepts for accelerated approval in late-line RRMM. Additional risks include duration of response proving insufficient, neutropenia becoming more clinically problematic at scale, or the FDA shifting its accelerated approval bar upward for this line of therapy given the broader IMiD/CELMoD degrader competition.
Unlock the full thesis for CCCC.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.